AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
Another solstice for CTLA-4
Solstice Oncology acquires porustobart from Harbour Biomed.
The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
Pfizer mimics pumitamig in gastroesophageal cancers
The company will start a phase 2/3 trial of PF-08634404 in March.
Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
Crescent moves to close the bispecific gap
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
